MOTS-c
A naturally occurring mitochondrial-derived peptide studied in animals for metabolism, insulin sensitivity and exercise capacity. Human evidence is very limited and it is not an approved drug.
Quick take
- What it is: a small peptide encoded within mitochondrial DNA — a "mitochondrial-derived peptide."
- What people study it for: metabolism, insulin sensitivity and exercise/mitochondrial function.
- What we actually know: interesting metabolic effects in mice and cells; published human trials are essentially absent.
- Status: not an approved drug; treated as a prohibited substance in sport.
What it is
MOTS-c is a mitochondrial-derived peptide — a short peptide encoded within mitochondrial DNA rather than the cell nucleus. It is part of a small, intriguing class of peptides that appear to act as signaling molecules influencing metabolism. It is a research compound, not an approved drug.1
Because it is naturally produced in the body, MOTS-c is studied as a window into how mitochondria communicate with the rest of the cell — and as a potential metabolic target.
How it works
Research suggests MOTS-c influences metabolic pathways, including effects related to insulin sensitivity, glucose handling and energy metabolism, partly through pathways such as AMPK. Some work also links it to the cellular response to exercise, where it has been reported to move into the nucleus and affect gene expression under metabolic stress.1,2 These mechanisms are biologically interesting but are characterized mainly in animal and cell systems.
What the evidence shows
Animal studies
Most MOTS-c research is preclinical. In mice and cell models it has been associated with improved metabolic measures, enhanced insulin sensitivity and effects on exercise capacity and metabolic stress responses.2,3 These findings drive its reputation as a “metabolic” and “exercise-mimetic” peptide.
Human studies
Published, peer-reviewed human clinical trials are essentially absent. Observations linking circulating MOTS-c levels to metabolic states exist, but controlled trials of administering MOTS-c in people are lacking.3 Human relevance, effective dose and safety are therefore not established.
Dosages reported in the literature
Informational only. The figures below describe doses reported in research settings; they are not a recommendation or a prescription. MOTS-c is not approved, and no human dose-finding trials exist to define a safe or effective range.
| Setting | Route | Reported range |
|---|---|---|
| Animal studies (scaled) | Injection | Varies widely; not directly applicable to humans |
| Anecdotal / clinic | Subcutaneous | Reported in microgram-to-milligram ranges; not validated |
Because there are no dose-finding human trials, no range here should be read as established as safe or effective.
Safety & side effects
There are no long-term controlled human safety studies for MOTS-c, so its real risk profile is genuinely unknown.3 As with other unregulated peptides, a practical concern is product quality — purity, dose accuracy and contamination vary between sources.
Legal & regulatory status
MOTS-c is not approved by the FDA for any use; it is a research compound. In sport, non-approved substances and metabolic modulators fall under anti-doping rules, so it should be treated as prohibited for athletes subject to those rules; check current WADA guidance. Rules differ by country and change over time.4
References
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015 Mar 3;21(3):443-454. [PMID 25738459, doi:10.1016/j.cmet.2015.02.009]
- Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metabolism. 2018 Sep 4;28(3):516-524.e7. [PMID 29983246, doi:10.1016/j.cmet.2018.06.008]
- Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology. 2023 Jan 24;14:1120533. (Exercise findings: Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021 Jan 20;12(1):470.) [PMID 36761202, PMID 33473109, doi:10.3389/fendo.2023.1120533, doi:10.1038/s41467-020-20790-0]
- World Anti-Doping Agency. The 2026 Prohibited List, International Standard. Section S0 (Non-Approved Substances) — any pharmacological substance with no current approval by a governmental regulatory health authority for human therapeutic use is prohibited at all times. In force 1 January 2026. [wada-ama.org, wada-ama.org]